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A B S T R A C T
Combinational therapy of lamivudine and oxymatrine has been employed in the battle against
hepatitis B virus in clinical setting. However, the pharmacokinetic behavior of the drug or
active metabolism in intravenous/oral co-administration regime is poorly investigated. Herein,
we evaluated the pharmacokinetic characteristic through a tailor-designed 3 way crossover-
Latin square experiment in adult male beagle dogs. Six dogs were randomly treated by
intravenous administration of lamivudine (2.5 mg/kg), oxymatrine (15 mg/kg) and combi-
national dosage, named as intravenous regime. Meanwhile the other six dogs were orally
administrated with lamivudine (2.5 mg/kg), oxymatrine (15 mg/kg) and combinational dosage,
named as oral regime. The pharmacokinetic feature in simultaneous oral treatment ap-
peared to have no significant difference when compared with individual administration,
even including matrine, the active metabolite of oxymatrine. In intravenous regime, the main
pharmacokinetic parameters of simultaneous administration were nearly consistent with
intravenous regime remedy.The collaborated application of lamivudine and oxymatrine con-
tributed to non-distinctive pharmacokinetic fluctuations of beagle dogs in intravenous/
oral regime, compared with individual employment, which established a vital base for the
clinical co-administration against hepatitis B. Furthermore, the present study demon-
strated that the determination of pharmacokinetics between combinational and individual
therapy might assist in the development of drug compatibility in clinical therapy.
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More than 240 million individuals around the world have suf-
fered from chronic hepatitis B virus (HBV) infection, which is
a DNA virus characterized by its reverse transcription for rep-
lication in infected hepatocytes [1–4]. At present, the therapy
options mainly depend on nucleotide analogues (NA) and in-
terferon alpha (INF-α) [5]. Lamivudine (3TC, Fig. 1A), possessing
anti-HBV replicated function, was the first approved oral NA.
However, 3TC-resistance phenomena, such as viral drug-
resistance and dose-dependent side effects [6], will be likely
to emerge in the long-term treatment when using 3TC alone
due to the emergence of drug resistance mutations in poly-
merase protein. To deal with the challenge, co-administrated
therapeutic strategy combining 3TC with other antiviral drugs
appeared [7–9]. Furthermore, the collaborated employment of
lamivudine and oxymatrine could significantly decrease the
conversion rate of HBVDNA and hepatitis B e antigen (HBeAg)
in patients when compared with mono-therapy of 3TC because
of the ability of oxymatrine to inhabit the development of drug
resistance to 3TC [6,10–13].
Oxymatrine (OM, Fig. 1B) is a major quinolizidine alkaloid
from the Chinese herb Sophora alopecuraides L., Sophora
subprostrata and Sophora flavescens Ait., and has been exten-
sively used as liver protecting drugs in the treatment of liver
ailments in traditional Chinese medicines (TCM) [14]. OM and
its active metabolite matrine (M, Fig. 1C) have been proven to
have an active antiviral effect on HBV infection in the clini-
cal trials [6,8,11,15,16]. And Xiaoyan Cui reported the superiority
of the combination of 3TC with oxymatrine or matrine over
3TC alone [6].
Although the single use of 3TC to treat HBV has largely been
replaced by more effective combination with OM, which has
been demonstrated previously in the literature, the impact of
combination therapy on the pharmacokinetics of each drug or
its active metabolite is largely unknown [6]. Herein, the present
study is carried out to investigate the effects of OM on the phar-
macokinetics of 3TC and to characterize the pharmacokinetic
behavior of OM and 3TC during co-administration to beagle
dogs following intravenous or oral administration.Whether or
not there are significant pharmacokinetic interactions, the
results of which will assist in the development of this two-
drug combination in clinical therapy strategy.
2. Materials and methods
2.1. Chemicals
3TC (content >98.5%) was purchased from Hefei Scenery Chemi-
cal Co., Ltd. (Hefei, Anhui, China). Standard OM, M and
famotidine (internal standard) were supplied by the National
Institute for the Control of Pharmaceutical and Biological Prod-
ucts (Beijing, China). Bulk OM (content >98.5%) was purchased
from Ningxia Bo-er-tai-li Pharmaceutical Co. Ltd. (Yinchuan,
Ningxia, China). Acetonitrile was of HPLC grade and other
chemicals were of analytical grade.
2.2. Animals
Twelve healthy adult male beagle dogs (Laboratory Animal
Center of Shenyang Pharmaceutical University, Shenyang, Lia-
oning, China) weighing 10 ± 1.3 kg (mean ± standard error) were
used for the pharmacokinetic study. The animal experimen-
tal protocols described belowwere approved by theAnimal Care
and Use Committee at Shenyang Pharmaceutical University.
2.3. Pharmacokinetic experiments
A randomized 3-way crossover-Latin square experiment with
a washout period of 1 week was designed. Dogs (n = 6) were
randomly assigned to groups to characterize the pharmaco-
kinetics and interaction of 3TC (2.5 mg/kg) and OM (15 mg/
kg) given intravenously alone and in combination. Another six
dogs were used to characterize the pharmacokinetics and in-
teraction of 3TC (5.0 mg/kg) and OM (30 mg/kg) given orally
alone and in combination. The dogs were housed in standard
stainless-steel cages under a 12 h light/dark cycle with access
to water and standard laboratory diet. The drugs were admin-
istered to all dogs following an overnight fast, and access to
food was restored 4 h after dosing. In the intravenous admin-
istration study, blood samples were collected prior to drug
administration and at 2, 5, 10, 15, 30, 45, 60, 90, 120, 150, 180,
240, 360 and 480 min after dosing through an intravenous cath-
eter placed in the opposite foreleg vein. In the oral
administration study, blood samples were collected prior to drug
administration and at 10, 20, 30, 45, 60, 90, 120, 150, 180, 240,
300, 360, 540 and 720 min after dosing through an intrave-
Fig. 1 – Structures of 3TC, OM and M (A-3TC; B-OM; C-M).
642 a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 1 ( 2 0 1 6 ) 6 4 1 – 6 4 7
nous catheter placed in the foreleg vein. The blood samples
were centrifuged immediately, and plasma was stored at –20 °C
until analysis.
2.4. Assay of 3TC, OM and M
The 3TC, OM and M concentrations in dog plasma were de-
termined by means of the HPLC-UV method reported. Briefly,
the analytes and internal standard were simultaneously ex-
tracted from plasma samples with OASIS® HLB Extraction
Cartridges (1 cc, 30 mg,Waters, Corp.), and separated on a C18
column with an isocratic mobile phase consisting of 13% ace-
tonitrile in 5 mmol/l sodium heptanesulfonate with the pH
adjusted to 3.2 with phosphoric acid. The UV absorbance was
monitored at 220 nm, and the column temperature was main-
tained at 40 °C. The linear calibration curves of the analytes
were obtained in the concentration range of 0.1 ~ 40 mg/l
(r2 > 0.999).The lower limit of quantification of the method was
0.1 mg/l for these analytes.The method was evaluated in terms
of recovery, accuracy and precision. The recoveries extraction
of 3TC, OM and M was ≥ 70%. Accuracy and precision for the
determination fell well within the limits of acceptability (<15%).
2.5. Pharmacokinetic analysis
The maximum concentration (Cmax) and corresponding peak
time (Tmax) were determined by the inspection of the indi-
vidual drug plasma concentration–time profiles.The elimination
rate constant (ke) was obtained from the least-squares fitted
terminal log-linear portion of the plasma concentration–
time profile.The elimination half-life (t1/2) was calculated from
0.693/ke.The area under the curve from zero to infinity (AUC0~∞)
was calculated using the trapezoidal rule with extrapolation
to infinity with ke. The mean residence time from zero to in-
finity (MRT) was estimated by moment analysis. The total
clearance from plasma (CL) was calculated as dose/AUC0~∞.The
steady-state volume of distribution (Vss) was calculated using
(dose ×AUMC0~∞)/(AUC0~∞)2. The relative bioavailability (Fr) was
calculated as AUCco-administration/AUCalone. The oral bioavailability
(F) was calculated using (AUCp.o. × dosei.v.)/(AUCi.v. × dosep.o.).
2.6. Statistical analysis
Data are expressed as the mean ± standard error (SE). Com-
parisons between co-administration and single-administration
groups were performed using the pairwise Student’s two one-
sided t-test, and differences were considered statistically
significant when P < 0.05.
3. Results and discussion
3.1. Pharmacokinetics of 3TC
The plasma concentrations of 3TC were measured by the vali-
dated UPLC method as reported in our previous study. Fig. 2
shows the mean plasma concentration–time profiles for 3TC
after either oral or intravenous administrations of 3TC, alone
and in combination with OM. The pharmacokinetic param-
eters for 3TC are demonstrated in Table 1. The absorbed
fractions of 3TC, a ratio of the AUCs for single oral or co-
combination of OM oral administration to single intravenous
administrations, were 80.5% and 73.3%, respectively.There were
no statistically significant differences in the main pharmaco-
kinetic parameters of 3TC between mono-therapy and co-
administration with OM after either oral or intravenous
administrations, despite the appearance of a 13.4% increase
in the intravenousAUC0~∞ (from 6.35 ± 1.62 to 5.50 ± 0.68 μg·h/
ml) (P > 0.05).The results indicated no pharmacokinetic changes
in 3TC following oral or intravenous administration when in
combination with OM to beagle dogs.
3.2. Pharmacokinetics of OM
The plasma concentrations of OM were measured by the vali-
dated UPLC method as reported by Piao et al. [17]. The mean
pharmacokinetic parameters of OM are summarized in Table 2
and the corresponding mean plasma concentration–time pro-
files for OM are illustrated in Fig. 3. In the case of the
pharmacokinetics of OM following intravenous mono- and
Fig. 2 – (A) Mean plasma 3TC concentration–time curves
following two intravenous regimens involving a single
dose of 2.5 mg/kg 3TC to beagle dogs: alone (red line) and
in combination with a single dose of 15 mg/kg OM (blue
line). (B) Mean plasma 3TC concentration–time curves
following two oral regimens involving a single dose of
5.0 mg/kg 3TC to beagle dogs: alone (red line) and in
combination with a single dose of 30 mg/kg OM (blue line).
Each value represents the mean ± SE (n = 6).
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co-administration with 3TC, the OM concentrations declined
in a bi-exponential manner. Furthermore, the fractions of OM
orally absorbed, determined by the ratio of AUCs, with and
without oral 3TC, to intravenous administration alone were
30.9% and 26.3%, respectively. In spite of the approximate 10%
differences illustrated in main pharmacokinetic parameters,
no statistically significant pharmacokinetic interactions were
observed following intravenous or oral co-administration of OM
between mono- and co-administration (P > 0.05).
3.3. Pharmacokinetics of M
In the case of the active metabolite of OM, Fig. 4 shows the
mean plasma concentration–time profiles of M after admin-
istration of OM alone and in combination with 3TC [18]. The
pharmacokinetic parameters for M are presented in Table 3.
Following intravenous administration, the concentrations of
M in plasma were generally lower than those of its parent com-
pound. After oral administration, the Cmax (12.30 ± 4.10 and
10.06 ± 2.88 μmol/l) and AUC0~∞ (56.31 ± 19.13 and 50.64 ± 8.25
μmol·h/l) were approximately four-fold higher than the intra-
venous Cmax (2.87 ± 0.85 and 2.59 ± 0.16 μmol/l) and AUC0~∞
(6.64 ± 1.59 and 7.90 ± 2.23 μmol·h/l). As illustrated in Fig. 4A,
OM was immediately biotransformed into M, as the Cmax was
reached in the first collected sample. In oral regimen of OM
alone or concomitantly with 3TC, the Tmax values of M were
3.75 ± 0.36 and 4.50 ± 0.22 h, respectively, and the concentra-
tions of M in plasma were higher than those of OM in the
following time-point. The oral biotransformation rates of OM
were 49.8% and 51.2% following single and combinational
therapy, respectively. On the basis of the equimolecular trans-
formation of OM into M [8,13], the absorbed total fractions of
OM, calculated by the ratio of the AUCs of OM plus M for single
oral and 3TC-containing oral administration to single intra-
venous administrations, were 57.4% and 50.3%, respectively.
The difference in these pharmacokinetic parameters was evalu-
ated to be statistically insignificant (P > 0.05), indicating that
there were no pharmacokinetic interactions involving the me-
tabolism of OM following both oral and intravenous
administration in combination with 3TC.
3TC is not significantly metabolized and is eliminated pri-
marily as unchanged drug via the kidneys. Approximately 5%
to 10% of the parent compound is metabolized to the phar-
macologically inactive trans-sulfoxide metabolites after a single
oral dose [11]. However, M, the metabolite of OM, is bioactive
and represents a primary reduction pathway by intestinal bac-
teria and liver [12,13]. So it is necessary to investigate
simultaneously the pharmacokinetic behavior of M and OM
after OM administration.
After mono-administration in this study, 3TC was rapidly
eliminated after both intravenous and oral administration, and
had excellent oral bioavailability (Tmax = 1.25 h, F = 80.5%).
However, compared with the findings of Hussey et al. (CL = 0.36
l/h/kg) [10], the higher values observed in our study (0.57 ± 0.12
l/h/kg) are probably due to the exclusion of samples taken 8 h
after intravenous dosing alone. Furthermore, the CL andVss fol-
Table 1 – Pharmacokinetics of 3TC following intravenous and oral administration alone and in combination with OM.
Intravenous administration Oral administration
Alone Combination P (95% CI) Alone Combination P (95% CI)
Cmax (μg/ml) – – – 4.12 ± 0.48 3.75 ± 0.82 0.64
Tmax (h) – – – 1.25 ± 0.11 1.08 ± 0.20 0.36
t1/2 (h) 1.79 ± 0.19 1.81 ± 0.16 0.93 1.76 ± 0.19 1.58 ± 0.16 0.53
AUC0~∞ (μg·h/ml) 6.35 ± 1.62 5.50 ± 0.68 0.55 10.22 ± 0.99 9.31 ± 1.30 0.66
MRT (h) 2.05 ± 0.19 2.09 ± 0.16 0.91 2.63 ± 0.14 2.95 ± 0.13 0.12
CL (l/h/kg)a 0.57 ± 0.12 0.53 ± 0.07 0.75 0.51 ± 0.05a 0.59 ± 0.08a 0.52
Vss (l/kg)b 1.03 ± 0.20 1.07 ± 0.14 0.86 1.35 ± 0.16b 1.77 ± 0.28b 0.29
Fr (%) 86.71 91.10
a Apparent oral clearance (CL/F) was calculated as dose/ AUC0~∞.
b Apparent oral steady-state volume of distribution (Vss/F) was calculated as (dose × AUMC0~∞)/(AUC0~∞)2.
Table 2 – Pharmacokinetics of OM following intravenous and oral administration alone and in combination with 3TC.
Intravenous administration Oral administration
Alone Combination P (95% CI) Alone Combination P (95% CI)
Cmax (μmol/l) – – – 21.64 ± 2.70 23.46 ± 3.87 0.69
Tmax (h) – – – 1.25 ± 0.17 1.08 ± 0.14 0.52
t1/2 (h) 1.51 ± 0.15 1.35 ± 0.16 0.48 2.18 ± 0.31 2.14 ± 0.26 0.91
AUC0~∞ (μmol·h/l) 91.85 ± 22.49 82.42 ± 10.53 0.54 56.82 ± 8.92 48.36 ± 8.36 0.30
MRT (h) 2.19 ± 0.29 1.92 ± 0.18 0.16 2.85 ± 0.19 2.61 ± 0.13 0.32
CL (l/h/kg) 0.76 ± 0.15 0.74 ± 0.09 0.86 2.28 ± 0.38a 2.64 ± 0.35a 0.38
Vss (l/kg) 1.57 ± 0.27 1.37 ± 0.12 0.52 6.65 ± 1.25b 6.97 ± 1.08b 0.84
Fr (%) 89.73 85.11
a Apparent oral clearance (CL/F) was calculated as dose/ AUC0~∞.
b Apparent oral steady-state volume of distribution (Vss/F) was calculated as (dose × AUMC0~∞)/(AUC0~∞)2.
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lowing intravenousmono-administration of 3TCwere consistent
with the allometric estimation according to CL,Vss and species
body weight (W): CL = 0.74 × W0.76, Vss = 1.09 × W0.94. The esti-
mates of CL andVss (0.48 l/h/kg and 0.95 l/kg, respectively) were
similar to the observed values for dogs in this study (0.57 ± 0.12
l/h/kg and 1.03 ± 0.20 l/kg, respectively).
In our study, following intravenous administration of OM
alone, theVss of 1.57 ± 0.27 l/kg is slightly greater than the total
body fluid of dogs, and larger than the value of 3TC (1.03 l/kg)
in dogs. This suggests that OM may undergo intracellular dis-
tribution and freely penetrate tissues beyond the systemic
circulation, and that the concentration of OM distributing in
tissues might be higher than that of blood vessels. Mean-
while, the phenomenon of biotransformation from OM to M
was also observed in our investigation, which was consistent
with previous studies showing that OM and its metabolite M,
after intramuscular injection, undergo wide tissue distribu-
tion in mice or rats, including the kidney, liver, lung, bone
marrow, spleen, and heart [12].Additionally, OM is rapidly elimi-
nated (t1/2 = 1.51 ± 0.15 h) after intravenous administration and
the oral bioavailability of OM plus M for single oral adminis-
tration to single intravenous administration was about 57.4%
in our investigation.
It was seen in the oral regimen that the estimate of OM
transformed into M (49.8%) was in conformity with that ob-
tained previously from a single-dose study with dogs (56.5%)
[18]. In addition, the bioconversion of M after intravenous ad-
ministration of OM was less than 10%. The ratio of the AUC
of M after intravenous dosing to oral dosing is roughly re-
garded as reflection of the metabolism by liver compared to
the sum of the metabolism by liver and gastrointestinal bac-
teria. Therefore, the results suggested that the reduction
metabolism of OM by gastrointestinal bacteria was four times
higher than that of liver and gastrointestinal bacteria is the
main pathway of OM metabolism. In this study, it was also in-
dicated that the relatively large individual variance of
pharmacokinetic parameters of OM and that of M emerged.
This may be attributable to the facts that OM is metabolized
via hepatic and intestinal bacteria pathways, and that the
hepatic function and the flora distribution are individualized.
The pharmacokinetic parameters of 3TC obtained from co-
administration in this study with beagle dogs are consistent
Fig. 3 – (A) Mean plasma OM concentration–time curves
following two intravenous regimens involving a single
dose of 15 mg/kg OM to beagle dogs: alone (red line) and in
combination with a single dose of 2.5 mg/kg 3TC (blue
line). (B) Mean plasma OM concentration–time curves
following two oral regimens involving a single dose of
30 mg/kg to beagle dogs: alone (red line) and in
combination with a single dose of 5.0 mg/kg 3TC (blue
line). Each value represents the mean ± SE (n = 6).
Fig. 4 – (A) Mean plasma M concentration–time curves
following two intravenous regimens involving a single
dose of 15 mg/kg OM to beagle dogs: alone (red line) and in
combination with a single dose of 2.5 mg/kg 3TC (blue
line). (B) Mean plasma M concentration–time curves
following two oral regimens involving a single dose of
30 mg/kg to beagle dogs: alone (red line) and in
combination with a single dose of 5.0 mg/kg 3TC (blue
line). Each value represents the mean ± SE (n = 6).
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with those obtained from mono-administration (P > 0.05).
Changes in certain issues, such as protein binding, absorp-
tion, distribution, metabolism and excretion, are the basis of
many drug interactions. Changes in protein binding and me-
tabolism would not significantly affect the distribution and
elimination of 3TC, because its protein binding is low (<36%)
and metabolism represents only a minor route of elimina-
tion. Approximately 5% to 10% of the parent compound is
metabolized to the pharmacologically inactivemetabolite [11,19].
3TC is a highly soluble and permeable drug with a rapid dis-
solution rate.As a consequence, oral doses are rapidly absorbed
by passive diffusion across the intestinal membrane [14]. Fur-
thermore, its relatively low molecular weight (229 D) and low
plasma protein binding result in a wide distribution and free
penetration into tissues beyond the systemic circulation [11].
OM and M are unlikely to be able to affect these passive and
free penetration processes. Moreover, 3TC is eliminated pri-
marily unchanged drug via the kidneys by filtration and active
renal tubular secretion, in part via the renal organic cation trans-
port system [11]. Although OM and M are eliminated partially
via the kidney, this does not significantly affect either the extent
of absorption or the elimination of 3TC, as indicated by an
absence of significant changes in the AUC0~∞ and t1/2 of 3TC
(P > 0.05). These findings agree with published results of drug
interaction studies involving 3TC [11,12].
Furthermore, the pharmacokinetics of OM is not signifi-
cantly affected by co-administration of 3TC.The low potential
of OM for drug–drug interactions is similar to that of 3TC,
because the properties of OM are fairly similar to those of 3TC,
such as a low protein binding (29.36 ± 4.17%), relatively lowmo-
lecular weight (264 D), highly water soluble (more than 150 mg/
ml) character. In our laboratory, it has been shown that OM and
M mainly undergo passive diffusion across Caco-2 cell mem-
brane. Hence, it is little likely that there will be an interaction
involving interference with the process of absorption.This as-
sumption is also demonstrated by the Tmax values of OM and
3TC (1.25 h for the single-regimen and 1.08 h for the co-
regimen, respectively) after oral administration. 3TC did not
markedly affect either the extent of distribution or the elimi-
nation of OM, as shown by a lack of any significant change in
the Vss and CL of OM, respectively (P > 0.05).
4. Conclusion
There is no pharmacokinetic interaction when 3TC and OM are
co-administrated, either intravenously or orally, and the po-
tential for 3TC to interact with its metabolite M has been
examined to be low. And this study focused on the pharma-
cokinetic interactions in dogs to account for the collaborated
employment of lamivudine and oxymatrine. However, the clini-
cal pharmacokinetics remains to be studied for confirming this
conclusion. Notwithstanding this limitation, the study does pro-
vides the in vivo pharmacokinetic basis for supporting the recent
clinical practices that no dosage adjustment is needed and
serious adverse events are absent when lamivudine and
oxymatrine are co-administrated, which demonstrated that the
determination of pharmacokinetics between combinational and
individual therapy might assist the development of drug com-
patibility in clinical therapies.
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